Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Over an 8-month median follow-up on mavacamten in patients with obstructive hypertrophic cardiomyopathy, new AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to better understand the expected incidence of AF/AFL, HF, and other long-term outcomes of mavacamten treatment in obstructive hypertrophic cardiomyopathy.
Authors
- Olives Nguyen (ORCID: https://orcid.org/0009-0005-6801-0744)
- Miriam Elman (ORCID: https://orcid.org/0000-0003-3162-6500)
- Alfonso Mejia (ORCID: https://orcid.org/0000-0001-6017-7527)
- Daniel Kamna (ORCID: https://orcid.org/0009-0005-3680-7329)
- Ingy Mahana (ORCID: https://orcid.org/0000-0003-3237-2979)
- Ahmad Masri (ORCID: https://orcid.org/0000-0002-6390-6526)
- Hongya Chen (ORCID: https://orcid.org/0000-0002-8648-9251)
- Hailey Volk
Institutions
- Oregon Health & Science University (US)
- Wright State University (US)
- The Ohio State University (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1161/jaha.125.042488
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39